Literature DB >> 20092952

Late complications of chemotherapy in testicular cancer.

Kyriaki Pliarchopoulou1, Dimitrios Pectasides.   

Abstract

Cisplatin-based treatment has significantly increased survival in testicular cancer patients. Therefore, there has been enough interest for the late toxic effects of chemotherapy which affect the quality of life of the cancer survivors. These toxic effects may either persist or present long after the end of chemotherapy and involve the impairment of renal function, neurotoxicity, pulmonary toxicity and vascular disease. Also, a major issue experienced by a large number of patients is infertility, which has been improved due to modified surgical techniques, reduced treatment intensity, the use of sperm cryopreservation and methods of assisted reproduction. Physicians should also be aware of the risk of secondary malignancy development. Therefore, close follow-up of the testicular cancer survivors as well as, focus on minimizing treatment complications through improvement of treatment strategies are warranted. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20092952     DOI: 10.1016/j.ctrv.2009.12.011

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  8 in total

1.  Holiday pains: a case of radiation-induced mesenteric ischemia.

Authors:  Carlene L Chun; James Joye; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  Raynaud's of the tongue following chemoradiation for squamous cell carcinoma of the oropharynx.

Authors:  Amit Mittal; Bharat B Mittal
Journal:  Mol Clin Oncol       Date:  2016-12-07

3.  Community-based exercise program effectiveness and safety for cancer survivors.

Authors:  Emily Jo Rajotte; Jean C Yi; K Scott Baker; Lindsey Gregerson; Andréa Leiserowitz; Karen L Syrjala
Journal:  J Cancer Surviv       Date:  2012-01-13       Impact factor: 4.442

Review 4.  Emerging Role of Biomarkers in Testicular Germ Cell Tumors.

Authors:  Maryam Soleimani; Christian Kollmannsberger; Lucia Nappi
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

5.  RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma.

Authors:  Christine Hjorth Andreassen; Mette Lorenzen; John E Nielsen; Sam Kafai Yahyavi; Birgitte Grønkær Toft; Lars R Ingerslev; Christoffer Clemmensen; Lene Juel Rasmussen; Carsten Bokemeyer; Anders Juul; Anne Jørgensen; Martin Blomberg Jensen
Journal:  Br J Cancer       Date:  2022-04-13       Impact factor: 9.075

6.  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).

Authors:  Konstantinos Koutsoukos; Kimon Tzannis; Christos Christodoulou; Vasilios Karavasilis; Charalambos Bakoyiannis; Thomas Makatsoris; C N Papandreou; Dimitrios Pectasides; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  World J Urol       Date:  2015-09-26       Impact factor: 4.226

7.  Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy.

Authors:  Mette Linnert; Helle K Iversen; Julie Gehl
Journal:  Radiol Oncol       Date:  2012-11-09       Impact factor: 2.991

8.  Very late relapse of testicular tumour in combination with renal cancer and their retroperitoneoscopic removal.

Authors:  Mihály Murányi; Morshed Ali Salah; Béla Tállai; Mátyás Benyó; Tibor Flaskó
Journal:  Case Rep Med       Date:  2011-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.